Form 4: Cognition Therapeutics Director Jack A. Khattar Acquires Shares and Options

Director Jack A. Khattar acquired 8,500 shares and options in Cognition Therapeutics on June 7, 2024.

Summary

• On June 7, 2024, Jack A. Khattar, a director of Cognition Therapeutics, acquired 8,500 shares of common stock represented by restricted stock units (RSUs) and options to purchase 8,500 shares.
• The RSUs and options vest in full on the earlier of June 7, 2025, or the date of the Issuer's next annual meeting of stockholders, contingent upon continuous service as a director.
• The exercise price for the stock options is $1.95.
• Following the transaction, Khattar directly owns 14,500 shares of common stock and options for 8,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, which is generally seen as a good sign. However, it's a standard grant, so the impact is limited.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and options is contingent upon the director's continuous service, aligning their interests with the company's long-term performance.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. This transaction indicates a positive sentiment from a member of the board of directors.

Stakeholder Impact

• The transaction could positively influence shareholder sentiment due to the director's increased stake in the company.

Key Dates